PrintPrintEmail this pageEmail this page
Optimal Clinical Strategies for the Treatment of Relapsed Hodgkin’s Lymphoma

Course details

  • Activity Release Date: Tue, Jun 21 2016
  • Activity Expiration Date: Thu, Jun 21 2018
  • Activity Type: Enduring
  • ACPE - Pharmacy: 1.00
  • AMA: 1.00
  • ANCC: 1.00
  • Attendance: 1.00
  • CCMC: 1.00
  • ACPE - Pharmacy Technician: 1.00
This activity closed on June 22nd, 2018 and is no longer available for enrollments.

Intended Audience

This activity is designed to meet the educational needs of case managers, nurses, pharmacists, pharmacy technicians, physicians and other health care professionals (HCPs) who have an interest in relapsed Hodgkin’s lymphoma (rHL).

Activity Description

Hodgkin’s lymphoma (HL) is a rare malignancy involving the lymph nodes and lymphatic system. It is largely considered a curable disease; however, 10%–30% of patients with HL will relapse after primary treatment. Prognostic factor identification has become particularly important when examining patients with chemotherapy refractory disease and for patients with multiple relapses. Both the prognostic factors present and the number of factors are important to consider, and these factors are becoming an integral part of treatment decisions for rHL. Adverse prognostic factors including time to relapse, poor performance status, advanced stage at relapse and anemia have been shown to have an impact on survival and freedom from second relapse.

This webcast will discuss adverse prognostic factors for a patient with rHL, the prognostic factors that are often used to help drive treatment choices, late effects of treatment and how to properly monitor patients in the long-term setting. It will also explore new and emerging therapies for patients with rHL.

Learning Objectives
At the end of this educational activity, participants should be able to

  • Identify adverse prognostic factors at relapse
  • Describe the optimal treatment regimen for a patient with rHL
  • Develop a monitoring plan for the long-term complications of rHL treatment
  • Describe the efficacy and safety profiles of new and emerging therapies for patients with rHL

Presenter
Craig Moskowitz, MDCraig Moskowitz, MD
Steven A. Greenberg Chair in Lymphoma Research
Clinical Director, Division of Hematologic Oncology
Attending, Lymphoma and Adult Bone Marrow Transplant Services
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Medical College of Cornell University
New York, New York

About the Presenter
Dr. Craig Moskowitz received his medical degree from Wayne State University School of Medicine in Detroit in 1988. He completed his residency in Internal Medicine in 1991 and served as Chief Resident in 1992. He completed a Fellowship in Hematology/Oncology at Memorial Sloan Kettering Cancer Center (MSKCC) in 1995 and served as the Chief Fellow from 1993–1994. Dr. Moskowitz is currently the Steven A. Greenberg Chair in Lymphoma Research as well as the Clinical Director of the Hematologic Oncology Division at MSKCC. He is also a Member and Attending Physician at the Lymphoma and Adult Bone Marrow Transplant Services at MSKCC and a Professor of Medicine at Cornell University Medical College.

Dr. Moskowitz serves as principal investigator and co-investigator for a number of clinical trials aimed at improving the care of patients with lymphoma. His research has focused on improving the outcome of patients with poor-risk, diffuse, large, B-cell lymphoma (DLBCL) and Hodgkin lymphoma. He has conducted research along two tracks. The first is focused on improving therapy for patients with disease that has returned or is not responding to standard therapy (refractory disease), through the use of high-dose therapy and autologous stem cell transplantation as well as new agents that can be incorporated into salvage therapy. The second is aimed at developing risk-adapted strategies to optimize the treatment of newly diagnosed DLBCL by using the knowledge gained in the relapsed and refractory setting.

Dr. Moskowitz has been recognized for his research on a national level through multiple awards. He has lectured worldwide on lymphoma and stem cell transplantation. In addition, he is a member of the research council at MSKCC, and he is on the steering committees for the bi-annual international lymphoma conference in Lugano, Switzerland and the international Hodgkin lymphoma conference in Cologne, Germany.

Disclosures of Relevant Financial Relationships
In accordance with the ACCME Standards for Commercial SupportSM, OptumHealth Education requires all those involved in the development of activity content to disclose their relevant financial relationships. An individual has a relevant financial relationship if such person (or their spouse/partner) has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the activity content over which the individual has control. OptumHealth Education ensures that the content is independent of commercial bias.

Faculty Disclosure
Craig H. Moskowitz, MD, has disclosed the following relevant financial relationships:
Grants: Merck; Seattle Genetics, Inc.; Pharmacyclics
Consultant: Celgene Corporation; Genentech BioOncology; Merck; Seattle Genetics, Inc.

Activity Planners
Sarah Chart, RN
Senior Director
OptumHealth Education

Rebecca Gleason, RN
Activity Manager
OptumHealth Education

Tina Rydland, PharmD
Crystal Clear Rx
Denver, Colorado

Activity Planner Disclosures
Ms. Chart and Gleason reported that they are employees of and own stock in UnitedHealth Group.
Dr. Rydland has nothing to report.

Reviewer Disclosures
To ensure fair balance and avoid bias, the content for this activity has been reviewed by an independent medical expert with no relevant financial relationships.

Method of Participation
There are no fees for participating in or receiving credit for this activity.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

Participants will receive a certificate upon successful completion of the activity, which includes the following:

  • Completing the entire activity
  • Completing the Pre- and Post-activity Assessments, Activity Evaluation, and Application for Certificate of Credit forms

You must be logged into your account to participate in this activity. Get started by clicking “Begin” and viewing the “CE Info”; then follow the prompts at the bottom of the screen. At the end of the activity, you will be able to view, save or print your certificate of participation. The Area of Practice you indicated in your profile corresponds with your certificate type. A complete listing of all of your activities can be found under “My Account”, “My Activities.”

Accreditation Statement
Joint LogoOptumHealth Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.

Credit Designation Statements
Physicians
OptumHealth Education designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PAs
The American Academy of Physician Assistants (AAPA) accepts credit from organizations accredited by the ACCME.

Nurses
The participant will be awarded up to 1.00 contact hour(s) of credit for attendance and completion of supplemental materials.

Nurse Practitioners
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts credit from organizations accredited by the ACCME and ANCC.

Pharmacists
This activity is approved for 1.00 contact hour(s) ([0.10] CEU) in states that recognize ACPE.
Attending the full program will earn 1.00 contact hour(s). Unique Activity Number(s): 0860-0000-16-003-H01-P.

Pharmacy Technicians
This activity is approved for 1.00 contact hour(s) ([0.10] CEU) in states that recognize ACPE.
Attending the full program will earn 1.00 contact hour(s). Unique Activity Number(s): 0860-0000-16-003-H01-T.

Case Mangers
The Commission for Case Manager Certification has approved this program for a maximum of 1.00 clock hour(s) for Certified Case Managers (CCM).

Attendance
A certificate of attendance will be provided to learners upon completion of activity requirements, enabling participants to register with licensing boards or associations that have not been pre-approved for credits. To apply for credit types not listed above, participants should use the procedure established by the specific organization with which they wish to obtain credit.

Provided By
This activity is provided by OptumHealth Education.

Commercial Support
This activity is supported by Seattle Genetics.

Hardware/Software Requirements
To view this activity you will need Internet Explorer 7.0+ or Firefox 3.0+ with Windows Media Player 9+, RealPlayer 12+ or Adobe Flash Player 9+. Be sure to disable any pop-up blocking software prior to beginning this activity.

Learning Format: 
Enduring Material